Sign In
Buy IDYA
$34.91
+0.680 (+1.99%)
At Close: Jun 23, 2026
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
06:00am, Wednesday, 17'th Jun 2026
SOUTH SAN FRANCISCO, Calif., June 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that its Board of Directors has elect
IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like properties IDE892 has a CYP3A4 IC50 greater than 45 micromolar
Ideaya Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion In H2 2026
03:22am, Thursday, 11'th Jun 2026
IDEAYA Biosciences maintains a "Strong Buy" rating, driven by positive darovasertib data in uveal melanoma and robust clinical progress. The company's darovasertib + crizotinib met the mPFS primary en
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
04:05pm, Wednesday, 10'th Jun 2026
SOUTH SAN FRANCISCO, Calif., June 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the closing of its underwritten public offering of 7,222,225 shares of its common sto
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
11:00pm, Monday, 08'th Jun 2026
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants PR Newswire SOUTH SAN
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
10:22pm, Monday, 08'th Jun 2026
SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants.
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:01pm, Monday, 08'th Jun 2026
SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced that it intends to offer and sell up to $300.0 million of shares of its common stock a
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
06:00am, Wednesday, 03'rd Jun 2026
IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RA
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Li
Darovasertib combination resulted in a statistically significant and clinically meaningful improvement in median PFS vs. investigator's choice of therapy (ICT) – 6.9 months vs.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 29'th May 2026
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCI
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06:00am, Friday, 29'th May 2026
SOUTH SAN FRANCISCO, Calif., May 29, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeu
IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit
07:04pm, Tuesday, 26'th May 2026
IDEAYA Biosciences NASDAQ: IDYA executives highlighted recent clinical progress across the company's oncology pipeline during a fireside chat at TD Cowen's seventh annual Oncology Innovation Summit, w
IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference
06:00am, Tuesday, 26'th May 2026
SOUTH SAN FRANCISCO, Calif., May 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeu
IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing
07:07am, Monday, 25'th May 2026
IDEAYA Biosciences NASDAQ: IDYA Chief Executive Yujiro Hata said the precision oncology company is preparing for a busy 2026, led by regulatory and clinical milestones for darovasertib in metastatic u
